The Indian Supreme Court’s rejection of Novartis’s Glivec patent brought the increasingly tense debate about the balance between patent rights and access to medicines to the forefront. Anand Grover, who successfully represented the Cancer Patient Aid Association in the case, argues that the patent system may not be the best way to encourage drug research
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
High-earning businesses place most value on the depth of the external legal teams advising them, according to a survey of nearly 29,000 in-house counsel
In-house lawyers have considerable influence over law firms’ actions, so they must use that power to push their external advisers to adopt sustainable practices